GleamWall
中文EN

RGNX REGENXBIO Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1590877 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.6%
TTM net income YoY1.5%
TTM EPS YoY7.5%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-95.7%
Net margin-113.9%
FCF margin-100.6%
EBITDA margin-85.9%

Returns

ROE-113.2%
ROA-35.4%
ROIC (approx.)-150.2%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets68.2%
Debt / equity0.00x
Current ratio4.74x
Interest coverage-4.06x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$170.44M$83.33M
Cost of revenue—$33.57M
Gross profit—$49.76M
R&D expense$228.30M$208.52M
SG&A expense$82.86M$76.62M
Operating income-$161.20M-$233.35M
Interest expense$45.01M$12.66M
Pretax income-$193.88M-$227.10M
Income tax$0$0
Net income-$193.88M-$227.10M
EBITDA-$145.58M-$217.13M
EPS (basic)-3.76-4.59
EPS (diluted)-3.76-4.59
Weighted avg. shares (diluted)51.57M49.51M
Banking
Provision for credit losses—-$5.00M
Balance sheet
Cash & equivalents$34.47M$57.53M
Short-term investments$195.60M$177.16M
Receivables$26.38M$20.47M
Current assets$281.28M$278.00M
PP&E, net$104.86M$117.59M
Total assets$453.03M$465.99M
Current liabilities$118.09M$103.19M
Total liabilities$350.30M$206.34M
Shareholders' equity$102.73M$259.65M
Shares outstanding50.89M49.55M
Cash flow statement
Operating cash flow-$123.96M-$173.12M
Capital expenditure$2.41M$2.44M
Free cash flow-$126.38M-$175.56M
Investing cash flow-$15.87M$103.45M
Financing cash flow$116.77M$92.68M
Depreciation & amortization$15.62M$16.21M
Stock-based compensation$34.56M$38.46M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.